7.2 Clinical Risk Reduction, VTE Prophylaxis & Infection Prevention

7.2 Clinical Risk Reduction, VTE Prophylaxis & Infection Prevention

[!NOTE] ANCC Blueprint Focus: Hospital-acquired complications represent major sources of preventable morbidity, mortality, and financial penalty in cardiovascular nursing practice. ANCC exam items assess the nurse's expertise in applying validated VTE risk models, adjusting anticoagulants for renal insufficiency, recognizing contraindications to mechanical compression devices, adhering to CLABSI and CAUTI prevention bundles, and selecting patients who require endocarditis antibiotic prophylaxis.

Preventing hospital-acquired complications requires a proactive, bundle-driven nursing approach. In cardiovascular units, where patients frequently present with multi-organ comorbidities, indwelling vascular devices, and surgical wounds, rigorous risk stratification directly protects against catastrophic thromboembolic and infectious events.

---

Hospital-Acquired VTE Risk Assessment & Stratification

Hospital-acquired venous thromboembolism (comprising deep vein thrombosis [DVT] and pulmonary embolism [PE]) is the leading preventable cause of in-hospital death. Systematic risk stratification at admission and with any clinical change is mandatory.

Clinical Risk Assessment Models

• The Padua Prediction Score (Hospitalized Medical Patients):
  • Validated for acute medical admissions (e.g., heart failure, ACS, pneumonia).
  • High VTE Risk is defined as a cumulative score $\ge 4$, indicating a clear mandate for pharmacologic thromboprophylaxis.
  • Scoring criteria: Active cancer (3 points); previous VTE (3 points); reduced mobility / bed rest with bathroom privileges for $\ge 3$ days (3 points); known thrombophilia (3 points); recent trauma or surgery $\le 1$ month (2 points); age $\ge 70$ years (1 point); heart or respiratory failure (1 point); acute myocardial infarction or ischemic stroke (1 point); acute infection or rheumatologic disorder (1 point); obesity with $\text{BMI} \ge 30\text{ kg/m}^2$ (1 point); ongoing hormonal therapy (1 point).
• The Caprini Risk Assessment Model (Surgical & Cardiovascular Patients):
  • Widely utilized in cardiac surgery (CABG, valve replacement) and vascular procedures.
  • Categorizes surgical patients into: Low Risk (0–1 point: early ambulation alone); Moderate Risk (2 points: mechanical or pharmacologic prophylaxis); High Risk (3–4 points: pharmacologic prophylaxis +/- mechanical); and Highest Risk ($\ge 5$ points: dual pharmacologic and mechanical prophylaxis continued post-discharge).

---

Pharmacologic & Mechanical Thromboprophylaxis

Balancing thromboprophylaxis efficacy against surgical and systemic bleeding risk is a core nursing responsibility.

Heparin-Induced Thrombocytopenia (HIT) Surveillance

• Mechanism: Immune-mediated adverse drug reaction caused by IgG antibodies directed against platelet factor 4 (PF4)-heparin complexes. These complexes bind to platelet Fc receptors, triggering massive platelet activation, thrombin generation, and catastrophic arterial and venous thrombosis (HIT-thrombosis syndrome).
• Monitoring Protocol: Obtain baseline platelet count before initiating heparin or LMWH. Monitor platelet counts every 2 to 3 days from day 4 to day 14 of therapy (or within 24 hours if heparin was received in the preceding 100 days).
• The '4 Ts' Diagnostic Rule: Clinical suspicion must be triggered if the platelet count drops by $\ge 50%$ from baseline or falls below $100,000/\mu\text{L}$, even if the absolute nadir remains above $150,000/\mu\text{L}$.
• Immediate Nursing Actions:
  1. Immediately discontinue all heparin sources (including subcutaneous prophylactic doses, IV infusions, heparin line flushes, and heparin-coated vascular catheters).
  2. Never administer low-molecular-weight heparin as a substitute (cross-reactivity $>90%$).
  3. Avoid platelet transfusions (which add fuel to the prothrombotic fire).
  4. Initiate a non-heparin parenteral direct thrombin inhibitor (argatroban or bivalirudin) or fondaparinux.

Contraindications to Mechanical Compression Devices (SCDs / GCS)

Mechanical compression is vital when bleeding risks preclude anticoagulation, but the nurse must identify critical contraindications:

1. Severe Peripheral Artery Disease (PAD): Ankle-brachial index (ABI) $<0.5$, absent pedal pulses, or severe ischemic rest pain. External compression on severely stenotic or calcified arterial beds provokes microvascular occlusion, acute skin necrosis, and limb-threatening ischemia.
2. Known or Suspected Acute DVT / PE: Applying pneumatic compression over an existing, non-stabilized deep venous thrombus can dislodge the clot and precipitate a fatal pulmonary embolism.
3. Severe Peripheral Edema / Acute Congestive Heart Failure: Sudden compression and mobilization of large volumes of peripheral third-space fluid into the central circulation can acutely elevate left ventricular preload and trigger flash pulmonary edema.
4. Local Cutaneous Pathology: Active severe dermatitis, open leg ulcers, gangrene, recent skin graft, or extreme lower extremity deformity.

---

Device-Related Infection Prevention: CLABSI, CAUTI & SSI Bundles

Healthcare-associated infections (HAIs) are largely preventable through strict adherence to standardized clinical practice bundles.

1. Central Line-Associated Bloodstream Infection (CLABSI) Bundle

• Insertion Protocol:
  • Rigorous hand hygiene prior to catheter insertion and site manipulation.
  • Maximal Sterile Barrier Precautions: Mask, cap, sterile gown, sterile gloves, and a full-body sterile drape covering the patient from head to toe.
  • Skin Antisepsis: Alcoholic chlorhexidine gluconate solution (>0.5% chlorhexidine with 70% isopropyl alcohol). Apply with vigorous back-and-forth friction for at least 30 seconds; allow to air-dry completely (minimum 2 minutes) before venipuncture (chlorhexidine requires dry contact time for bactericidal action).
  • Anatomical Site Selection: The subclavian vein is the preferred site for non-tunneled central venous lines due to the lowest rate of infectious and thrombotic complications. The internal jugular vein is acceptable (though higher risk due to tracheostomy/oral secretions). The femoral vein should be strictly avoided in adult patients due to high microbial colonization and deep vein thrombosis risks.
• Maintenance Protocol:
  • 'Scrub the hub': Vigorously scrub catheter hubs, needleless connectors, and injection ports with chlorhexidine or 70% alcohol for at least 15 seconds (or utilize chlorhexidine-impregnated protective caps) prior to every access.
  • Change transparent semipermeable membrane dressings every 7 days (or every 48 hours for gauze dressings), and immediately if the dressing becomes damp, loose, or visibly soiled.
  • Daily Line Review: The nurse must evaluate catheter necessity on daily multidisciplinary rounds and advocate for immediate line removal when clear clinical indication ceases.

2. Catheter-Associated Urinary Tract Infection (CAUTI) Bundle

• Appropriate Indications: Urinary catheters must never be placed for convenience or routine incontinence management. Legitimate indications are restricted to: acute urinary retention or bladder outlet obstruction; precise hourly urine volume monitoring in hemodynamically unstable intensive care patients; open Stage 3 or 4 perineal/sacral pressure injuries in incontinent patients; prolonged surgical procedures; and comfort measures in end-of-life care.
• Aseptic Maintenance: Perform hand hygiene and insert using strict sterile technique with a small-bore catheter (14 to 16 French). Maintain a continuously closed drainage system.
• Gravity & Positioning: Keep the collection bag continuously below the level of the patient's bladder to prevent retrograde flow of colonized urine. Secure the catheter to the thigh to eliminate traction and urethral mucosal trauma. Ensure tubing remains free of dependent loops, kinks, and floor contact.
• Prompt Removal: Remove indwelling catheters within 24 to 48 hours postoperatively in cardiac surgical patients unless hemodynamic instability mandates continued hourly output titration.

3. Surgical Site Infection (SSI) Reduction Bundle

• Perioperative Glycemic Control: Maintain target perioperative blood glucose $<180\text{ mg/dL}$ (10.0 mmol/L) in both diabetic and non-diabetic cardiac surgery patients (CABG, valve replacement). Hyperglycemia severely suppresses neutrophil chemotaxis, phagocytosis, and bactericidal oxidative burst.
• Maintenance of Normothermia: Maintain core body temperature $\ge 36.0^\circ\text{C}$ ($96.8^\circ\text{F}$) throughout the intraoperative and immediate postoperative phases using active forced-air warming blankets. Hypothermia induces peripheral vasoconstriction, diminishes tissue oxygen tension at the surgical incision, and impairs platelet aggregation.
• Hair Removal Standard: If hair removal at the surgical site is necessary, use electric surgical clippers with a single-use disposable head immediately prior to surgery in the pre-op holding area. Manual razors are strictly prohibited because razor blades create microscopic cutaneous abrasions and epidermal micro-lacerations that become rapidly colonized by Staphylococcus aureus and skin flora.
• Antimicrobial Prophylaxis Timing & Dosing: Administer weight-adjusted prophylactic antibiotics (e.g., Cefazolin 2.0 g IV for $<120\text{ kg}$, or 3.0 g IV for $\ge 120\text{ kg}$) within 60 minutes prior to surgical incision (or within 120 minutes for vancomycin/fluoroquinolones). Re-dose intraoperatively if surgery exceeds 4 hours or blood loss exceeds 1,500 mL. Discontinue all prophylactic antibiotics within 24 to 48 hours post-cardiac surgery.

---

Infective Endocarditis (IE) Antibiotic Prophylaxis Guidelines

Contemporary American Heart Association / American College of Cardiology (AHA/ACC) guidelines strictly restrict antibiotic prophylaxis prior to dental procedures to only those patients at the highest risk of adverse outcomes from infective endocarditis.

                      [ High-Risk Cardiac Condition Present? ]
                                      │
               ┌──────────────────────┴──────────────────────┐
               │ YES                                         │ NO
               ▼                                             ▼
  1. Prosthetic heart valves (mechanical,           NO PROPHYLAXIS REQUIRED
     bioprosthetic, homograft, TAVR/TMVR)           (Native MVP, bicuspid aortic
  2. Prosthetic material for valve repair           valve, calcific AS, innocent
     (annuloplasty rings, clips, chords)            murmurs, pacemakers, ICDs,
  3. Previous episode of Infective Endocarditis     or coronary artery stents)
  4. Congenital Heart Disease (CHD):
     - Unrepaired cyanotic CHD (shunts)
     - Repaired CHD with prosthetic material
       during first 6 months post-procedure
     - Repaired CHD with residual defects at/near
       site of prosthetic patch/device
  5. Cardiac transplant recipients with valvulopathy
               │
               ▼
  [ Undergoing Dental Procedure Involving: ]
  - Gingival tissue manipulation
  - Periapical region of teeth manipulation
  - Perforation of the oral mucosa
               │
               ▼
  [ Guideline Antibiotic Regimen (30-60 min Pre-Procedure) ]
  - Standard Oral: Amoxicillin 2.0 g PO
  - Unable to take PO: Ampicillin 2.0 g IM/IV or Cefazolin 1.0 g IM/IV
  - Penicillin-Allergic: Cephalexin 2.0 g PO, Azithromycin/Clarithromycin 500 mg PO
    *(Clindamycin is NO LONGER recommended due to C. difficile risk)*

Critical Clinical Points on Endocarditis Prophylaxis

• Conditions NOT Requiring Prophylaxis: Native valvular heart disease (such as mitral valve prolapse with or without regurgitation, bicuspid aortic valve, calcific aortic stenosis), hypertrophic cardiomyopathy, innocent heart murmurs, ventricular septal defects repaired without prosthetic material after 6 months, coronary artery stents, and implanted pacemakers or ICDs.
• Procedures NOT Requiring Prophylaxis: Routine dental anesthetic injections through non-infected tissue, taking dental radiographs, placement of removable prosthodontic appliances, shedding of deciduous teeth, and bleeding from trauma to the lips or oral mucosa.
• The Removal of Clindamycin: In 2021, the AHA officially removed clindamycin from the recommended prophylaxis regimens for penicillin-allergic patients due to its substantial risk of inducing lethal Clostridioides difficile colitis and increasing resistance among viridans group streptococci.